CL2019000271A1 - Inhibidores de polimerasa hcv. (divisional solicitud 201600493) - Google Patents
Inhibidores de polimerasa hcv. (divisional solicitud 201600493)Info
- Publication number
- CL2019000271A1 CL2019000271A1 CL2019000271A CL2019000271A CL2019000271A1 CL 2019000271 A1 CL2019000271 A1 CL 2019000271A1 CL 2019000271 A CL2019000271 A CL 2019000271A CL 2019000271 A CL2019000271 A CL 2019000271A CL 2019000271 A1 CL2019000271 A1 CL 2019000271A1
- Authority
- CL
- Chile
- Prior art keywords
- divisional application
- hcv polymerase
- polymerase inhibitors
- inhibitors
- prophylaxis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA INVENCIÓN PROPORCIONA COMPUESTOS DE LA FÓRMULA (I) EN DONDE B ES UNA NUCLEOBASE SELECCIONADA DE LOS GRUPOS (A) A (D) Y LAS OTRAS VARIABLES SON COMO SE DEFINE EN LAS REIVINDICACIONES, LOS CUALES SON PARA USO EN EL TRATAMIENTO O PROFILAXIS DE INFECCIÓN POR VIRUS DE HEPATITIS C, Y ASPECTOS RELACIONADOS.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1351026 | 2013-09-04 | ||
| SE1351169 | 2013-10-03 | ||
| SE1450152 | 2014-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000271A1 true CL2019000271A1 (es) | 2019-06-07 |
Family
ID=52628746
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016000493A CL2016000493A1 (es) | 2013-09-04 | 2016-03-03 | Inhibidores de polimerasa hcv. |
| CL2019000271A CL2019000271A1 (es) | 2013-09-04 | 2019-02-01 | Inhibidores de polimerasa hcv. (divisional solicitud 201600493) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016000493A CL2016000493A1 (es) | 2013-09-04 | 2016-03-03 | Inhibidores de polimerasa hcv. |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US9481703B2 (es) |
| EP (2) | EP3041855B1 (es) |
| JP (2) | JP6456958B2 (es) |
| KR (1) | KR20160078337A (es) |
| CN (3) | CN108676047B (es) |
| AU (2) | AU2014315715B2 (es) |
| BR (1) | BR112016004919A2 (es) |
| CA (1) | CA2921899A1 (es) |
| CL (2) | CL2016000493A1 (es) |
| CR (1) | CR20160123A (es) |
| CY (1) | CY1119587T1 (es) |
| DK (1) | DK3041855T3 (es) |
| EA (1) | EA028974B1 (es) |
| HK (2) | HK1221228A1 (es) |
| HR (1) | HRP20171435T1 (es) |
| HU (1) | HUE036365T2 (es) |
| IL (2) | IL244389B (es) |
| ME (1) | ME02875B (es) |
| MX (1) | MX2016002849A (es) |
| MY (1) | MY177804A (es) |
| PH (2) | PH12016500402B1 (es) |
| PL (1) | PL3041855T3 (es) |
| PT (1) | PT3041855T (es) |
| RS (1) | RS56383B1 (es) |
| SA (1) | SA516370684B1 (es) |
| SG (2) | SG10201700647PA (es) |
| SI (1) | SI3041855T1 (es) |
| UA (1) | UA117375C2 (es) |
| WO (1) | WO2015034420A1 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ599404A (en) | 2009-09-21 | 2014-02-28 | Gilead Sciences Inc | Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs |
| CN103052631B (zh) | 2010-07-22 | 2015-11-25 | 吉里德科学公司 | 用于治疗副黏病毒科病毒感染的方法和化合物 |
| CN104151360B (zh) * | 2013-05-14 | 2019-02-22 | 北京美倍他药物研究有限公司 | 磷酸/膦酸衍生物及其医药用途 |
| UA117375C2 (uk) * | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
| RU2016125213A (ru) | 2013-11-27 | 2017-12-29 | АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи | Нуклеотиды для лечения рака печени |
| US20170198005A1 (en) * | 2013-11-27 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| EP3134423A4 (en) * | 2014-04-24 | 2017-11-29 | Cocrystal Pharma, Inc. | 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
| CN105315319B (zh) * | 2014-07-30 | 2020-11-20 | 南京圣和药业股份有限公司 | 丙型肝炎病毒抑制剂及其应用 |
| TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| UA121562C2 (uk) | 2014-12-30 | 2020-06-25 | Дау Аґросаєнсиз Елелсі | Сполуки аміду з фунгіцидною активністю |
| US10252989B2 (en) | 2014-12-30 | 2019-04-09 | Dow Agrosciences Llc | Picolinamides with fungicidal activity |
| KR20170099929A (ko) | 2014-12-30 | 2017-09-01 | 다우 아그로사이언시즈 엘엘씨 | 살진균 활성을 갖는 피콜린아미드 화합물의 용도 |
| CN107426999B (zh) * | 2014-12-30 | 2023-01-20 | 美国陶氏益农公司 | 具有杀真菌活性的吡啶酰胺化合物 |
| WO2016134057A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
| BR112017018837A2 (pt) * | 2015-03-02 | 2018-04-24 | Medivir Ab | fórmula de fosforamidato de nucleotídeos |
| WO2016140615A1 (en) * | 2015-03-02 | 2016-09-09 | Medivir Ab | Nucleotide derivatives which are hcv inhibitors for use in the treatment of hepatitis c |
| WO2016160646A1 (en) * | 2015-04-02 | 2016-10-06 | Merck Sharp & Dohme Corp. | Process for making phosphoramidate protected nucleoside compounds |
| US10011629B2 (en) * | 2015-05-01 | 2018-07-03 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
| MX2018002707A (es) * | 2015-09-02 | 2018-08-01 | Abbvie Inc | Derivados de tetrahidrofurano antivirales. |
| WO2017040895A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040896A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040889A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040892A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040898A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| US10251904B2 (en) | 2015-09-16 | 2019-04-09 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
| CN105367505A (zh) * | 2015-12-01 | 2016-03-02 | 苏利制药科技江阴有限公司 | 一种新型合成3,6-二甲基-2,5-哌嗪二酮的方法 |
| EP3500584A1 (en) * | 2016-08-19 | 2019-06-26 | Sandoz AG | Sofosbuvir derivatives for the treatment of hepatitis c |
| EP4331677A3 (en) | 2017-03-14 | 2024-05-29 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| EP4219513A1 (en) | 2017-05-01 | 2023-08-02 | Gilead Sciences, Inc. | Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| TWI774761B (zh) | 2017-05-02 | 2022-08-21 | 美商科迪華農業科技有限責任公司 | 用於穀物中的真菌防治之協同性混合物 |
| JP7112429B2 (ja) | 2017-05-02 | 2022-08-03 | コルテバ アグリサイエンス エルエルシー | 芝草上の真菌疾患に対する殺菌剤としての非環式ピコリンアミド化合物の使用 |
| TW201842851A (zh) | 2017-05-02 | 2018-12-16 | 美商陶氏農業科學公司 | 用於穀類中的真菌防治之協同性混合物 |
| CN117982682A (zh) | 2017-07-11 | 2024-05-07 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
| BR102019004480B1 (pt) | 2018-03-08 | 2023-03-28 | Dow Agrosciences Llc | Picolinamidas como fungicidas |
| CA3094958A1 (en) | 2018-03-09 | 2019-09-12 | Medivir Aktiebolag | Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides |
| KR20210076072A (ko) | 2018-10-15 | 2021-06-23 | 코르테바 애그리사이언스 엘엘씨 | 옥시피콜린아미드의 합성 방법 |
| CN109762040A (zh) * | 2019-01-14 | 2019-05-17 | 歌礼生物制药(杭州)有限公司 | 一种核苷类ns5b聚合酶抑制剂的制备方法 |
| EP4096678A1 (en) | 2020-01-27 | 2022-12-07 | Gilead Sciences, Inc. | Methods for treating sars cov-2 infections |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN111269263A (zh) * | 2020-03-09 | 2020-06-12 | 上海龙翔生物医药开发有限公司 | 一种瑞德西韦侧链中间体及其制备方法 |
| EP4118085A2 (en) | 2020-03-12 | 2023-01-18 | Gilead Sciences, Inc. | Methods of preparing 1'-cyano nucleosides |
| AU2021251689B2 (en) | 2020-04-06 | 2024-06-13 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| CN111848679A (zh) * | 2020-04-17 | 2020-10-30 | 山东科巢生物制药有限公司 | 一种利用微通道反应技术合成瑞德西韦的方法 |
| AU2021281351A1 (en) | 2020-05-29 | 2023-01-19 | Gilead Sciences, Inc. | Remdesivir treatment methods |
| CN115996928A (zh) | 2020-06-24 | 2023-04-21 | 吉利德科学公司 | 1’-氰基核苷类似物及其用途 |
| EP4424372A2 (en) | 2020-08-27 | 2024-09-04 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| AU2023227794A1 (en) | 2022-03-02 | 2024-10-17 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| CN116199679A (zh) * | 2022-12-23 | 2023-06-02 | 吉斯凯(苏州)制药有限公司 | 一种拉米夫定的工业化制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10199053I1 (de) | 1992-12-29 | 2002-08-29 | Abbott Lab | Inhibitoren der retroviralen Protease |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| KR101201552B1 (ko) * | 2000-10-18 | 2012-11-15 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| US20090298708A1 (en) * | 2006-08-23 | 2009-12-03 | Masad Damha J | 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside 5'-triphosphates and their use in enzymatic nucleic acid synthesis |
| CN101573370B (zh) * | 2006-10-10 | 2013-09-11 | 美迪维尔公司 | Hcv核苷类抑制剂 |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| EP2234623A4 (en) | 2007-12-27 | 2012-03-28 | Epiphany Biosciences | ANTIVIRAL CONNECTIONS |
| US8173621B2 (en) * | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| AR074977A1 (es) | 2008-12-23 | 2011-03-02 | Pharmasset Inc | Sintesis de nucleosidos de purina |
| AU2010226466A1 (en) * | 2009-03-20 | 2011-10-20 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
| CN101591371B (zh) * | 2009-06-30 | 2012-05-30 | 连云港金康医药科技有限公司 | 一种通过卤交换氟化制备吉西他滨或其类似物的方法 |
| WO2011123672A1 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Purine nucleoside phosphoramidate |
| US8402690B2 (en) | 2010-09-09 | 2013-03-26 | Sterling International Inc. | Bedbug trap |
| WO2012040126A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| CA2810928A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| EP2696681B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013039920A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| LT2794627T (lt) | 2011-12-22 | 2019-01-10 | Alios Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai |
| US20140140951A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Rp-Nucleoside Analog |
| UA117375C2 (uk) * | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
| RU2016125213A (ru) * | 2013-11-27 | 2017-12-29 | АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи | Нуклеотиды для лечения рака печени |
| US20170198005A1 (en) * | 2013-11-27 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| EP3134423A4 (en) | 2014-04-24 | 2017-11-29 | Cocrystal Pharma, Inc. | 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
-
2014
- 2014-02-09 UA UAA201602085A patent/UA117375C2/uk unknown
- 2014-09-02 PT PT147894349T patent/PT3041855T/pt unknown
- 2014-09-02 EP EP14789434.9A patent/EP3041855B1/en active Active
- 2014-09-02 SG SG10201700647PA patent/SG10201700647PA/en unknown
- 2014-09-02 KR KR1020167008381A patent/KR20160078337A/ko not_active Application Discontinuation
- 2014-09-02 ME MEP-2017-229A patent/ME02875B/me unknown
- 2014-09-02 PL PL14789434T patent/PL3041855T3/pl unknown
- 2014-09-02 RS RS20170949A patent/RS56383B1/sr unknown
- 2014-09-02 MY MYPI2016700722A patent/MY177804A/en unknown
- 2014-09-02 HU HUE14789434A patent/HUE036365T2/hu unknown
- 2014-09-02 EA EA201690452A patent/EA028974B1/ru not_active IP Right Cessation
- 2014-09-02 CN CN201810472644.9A patent/CN108676047B/zh active Active
- 2014-09-02 CA CA2921899A patent/CA2921899A1/en not_active Abandoned
- 2014-09-02 DK DK14789434.9T patent/DK3041855T3/en active
- 2014-09-02 WO PCT/SE2014/051005 patent/WO2015034420A1/en active Application Filing
- 2014-09-02 JP JP2016540848A patent/JP6456958B2/ja active Active
- 2014-09-02 BR BR112016004919A patent/BR112016004919A2/pt not_active Application Discontinuation
- 2014-09-02 SG SG11201601474UA patent/SG11201601474UA/en unknown
- 2014-09-02 EP EP17176973.0A patent/EP3252066B1/en active Active
- 2014-09-02 CN CN201480060874.4A patent/CN105705510B/zh active Active
- 2014-09-02 MX MX2016002849A patent/MX2016002849A/es unknown
- 2014-09-02 SI SI201430401T patent/SI3041855T1/sl unknown
- 2014-09-02 CN CN201810473163.XA patent/CN108558973A/zh active Pending
- 2014-09-02 AU AU2014315715A patent/AU2014315715B2/en not_active Ceased
-
2015
- 2015-02-27 US US14/634,449 patent/US9481703B2/en active Active
-
2016
- 2016-02-29 PH PH12016500402A patent/PH12016500402B1/en unknown
- 2016-03-02 IL IL244389A patent/IL244389B/en not_active IP Right Cessation
- 2016-03-03 CL CL2016000493A patent/CL2016000493A1/es unknown
- 2016-03-06 SA SA516370684A patent/SA516370684B1/ar unknown
- 2016-03-10 CR CR20160123A patent/CR20160123A/es unknown
- 2016-07-14 US US15/210,500 patent/US9540411B2/en not_active Expired - Fee Related
- 2016-08-04 HK HK16109322.2A patent/HK1221228A1/zh unknown
- 2016-11-23 US US15/360,360 patent/US9828408B2/en not_active Expired - Fee Related
-
2017
- 2017-06-13 AU AU2017203954A patent/AU2017203954B2/en not_active Ceased
- 2017-09-25 HR HRP20171435TT patent/HRP20171435T1/hr unknown
- 2017-10-04 CY CY20171101032T patent/CY1119587T1/el unknown
- 2017-11-27 US US15/823,224 patent/US10106571B2/en not_active Expired - Fee Related
-
2018
- 2018-05-02 PH PH12018500931A patent/PH12018500931A1/en unknown
- 2018-09-12 IL IL261702A patent/IL261702B/en not_active IP Right Cessation
- 2018-10-12 JP JP2018193251A patent/JP2019065011A/ja not_active Ceased
- 2018-10-22 US US16/166,578 patent/US20190085010A1/en not_active Abandoned
- 2018-11-22 HK HK18114953.6A patent/HK1255872A1/zh unknown
-
2019
- 2019-02-01 CL CL2019000271A patent/CL2019000271A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019000271A1 (es) | Inhibidores de polimerasa hcv. (divisional solicitud 201600493) | |
| CR20160337A (es) | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b | |
| CO2017007355A2 (es) | Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b | |
| CR20160241A (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b | |
| CR20150611A (es) | Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis por el virus de la hepatitis b | |
| CO7170160A2 (es) | Nuevas 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infección del virus de la hepatitis b | |
| UY37997A (es) | Agentes antivirales contra la hepatitis b | |
| EA201590943A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| EA201690526A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| CL2020000487A1 (es) | Agentes antivirales contra la hepatitis b. | |
| EA201792069A1 (ru) | Производные азокана и азонана и способы лечения инфекций гепатита в | |
| CL2014003634A1 (es) | Inhibidores del virus de la hepatitis c | |
| CO6561783A2 (es) | Inhibidores del virus flaviviridae | |
| PE20150862A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| ECSP10010210A (es) | Compuestos nucleósidos antivirales | |
| UY35873A (es) | ?composiciones y métodos para el control de virus en el ácaro varroa y las abejas?. | |
| DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
| UY34066A (es) | Inhibidores del virus de la hepatitis c | |
| DOP2016000278A (es) | Nuevos compuestos macrocíclicos | |
| BR112016002638A2 (pt) | novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório | |
| EA201892246A1 (ru) | Производные аминотиазола, полученные в качестве противовирусных средств | |
| BR112017003663A2 (pt) | composto, composição, e, método para tratamento de infecção por hiv. | |
| AR095133A1 (es) | Formulación de combinación de dos compuestos antivirales |